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Polyurethane scaffolds seeded 
with CD34+ cells maintain 
early stem cells whilst also 
facilitating prolonged egress of 
haematopoietic progenitors
Charlotte E. Severn1,2, Hugo Macedo3, Mark J. Eagle4, Paul Rooney4, Athanasios Mantalaris3 & 
Ashley M. Toye1,2
We describe a 3D erythroid culture system that utilises a porous polyurethane (PU) scaffold to mimic 
the compartmentalisation found in the bone marrow. PU scaffolds seeded with peripheral blood CD34+ 
cells exhibit a remarkable reproducibility of egress, with an increased output when directly compared 
to human bone scaffolds over 28 days. Immunofluorescence demonstrated the persistence of CD34+ 
cells within the scaffolds for the entirety of the culture. To characterise scaffold outputs, we designed 
a flow cytometry panel that utilises surface marker expression observed in standard 2D erythroid 
and megakaryocyte cultures. This showed that the egress population is comprised of haematopoietic 
progenitor cells (CD36+GPA−/low). Control cultures conducted in parallel but in the absence of a scaffold 
were also generally maintained for the longevity of the culture albeit with a higher level of cell death. 
The harvested scaffold egress can also be expanded and differentiated to the reticulocyte stage. In 
summary, PU scaffolds can behave as a subtractive compartmentalised culture system retaining and 
allowing maintenance of the seeded “CD34+ cell” population despite this population decreasing in 
amount as the culture progresses, whilst also facilitating egress of increasingly differentiated cells.
The human body efficiently compartmentalises the red blood cell manufacturing process in the bone marrow, pro-
ducing 2.5 million reticulocytes per second for an entire lifetime using only a tiny contingent of haematopoietic 
stem cells (HSC). The HSCs in the bone marrow reside within the endosteal niche where they undergo symmet-
ric and asymmetric division1–5. HSCs differentiate to first a multipotent progenitor (MPP) and then a common 
myeloid progenitor (CMP) most often characterised as CD34+CD38+ 6–8. Once restriction to the megakaryocyte/
erythroid progenitor (MEP) stage occurs cells become; CD34+/GPA+ 9, CD34+/CD38low/+ 10, CD41+/GPA+ 11  
and more recently CD34+ cells were shown to progress from CD34+/CD36− as a CMP and then CD34+/
CD36+MEPs12,13. However there is now evidence that true CMP populations are a rare component of the hae-
matopoietic tree and instead bipotent cells are able to differentiate down the erythroid and megakaryocyte line-
ages or the myeloid and megakaryocyte lineages that arise directly from an MPP14,15. Upon lineage commitment 
cells express lineage specific markers such as GPA and band 3 for erythroid cells and CD42b and CD61 in the 
megakaryocyte lineage16–19. Lineage differentiation is dependant upon cytokines, namely erythropoietin (EPO) 
for erythroid development and thrombopoietin (TPO) for the generation of megakaryocytes and their progeni-
tors, although TPO is also known to influence HSCs20–26.
Successful protocols have been generated to produce reticulocytes using HSCs isolated from adult peripheral 
blood27–32, umbilical cord blood32–35 and embryonic stem cells36,37; although with varying yields of reticulocytes. 
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Proof of principle has also been provided for the safety of cultured RBC (cRBC), as 2.5 ml of packed reticulo-
cytes generated ex vivo were transfused into a single volunteer30. More recently 5 ml packed reticulocytes have 
been manufactured but further scale-up is required to reach an adult therapeutic dose31; these initial successes 
were achieved using static flasks or stirrer flasks30,31. The challenge going forward for cRBC production is that 
the current culture conditions cause HSCs to be rapidly pushed into erythroid lineage commitment, eventually 
exhausting the initial stem cell pool and limiting expansion capacity. Furthermore, high-density culture is dif-
ficult due to the increased likelihood of spontaneous terminal differentiation and so vast culture volumes are 
needed (reviewed in ref. 38 and 39).
One option is better recapitulation of the bone marrow structure and microenvironment to increase yields 
and longevity of erythroid cultures. Multiple research groups have attempted to recreate the honeycomb like 
architecture of the human bone marrow using three-dimensional scaffold culture systems with the ultimate aim 
of reproducing the whole of erythropoiesis within the scaffold environment. At present there is no consensus as 
to the optimal scaffold material, culture conditions or cell type to use for seeding, making direct comparisons 
between studies difficult. One approach is to seed HSCs directly onto scaffolds with a number of materials already 
investigated including the biocompatible PU used here40, hydrogels41, fibrin42, bio-derived bone43, PET44, and 
non-woven polyester disks45.
In this study we compare the output from a highly porous PU scaffold seeded with CD34+ cells to that pro-
duced from a de-cellularised human bone derived scaffold, with the aim of demonstrating compartmentalisation 
of early stem cells in the honeycomb structure. We describe techniques that assess the impact of changes on either 
scaffold occupancy or in scaffold egress following an alteration in culture conditions. Finally we demonstrate that 
static PU scaffold cultures offer the opportunity to harvest haematopoietic progenitors across a longer time period 
compared to traditional 2D cultures.
Results
Haematopoietic progenitors continuously egress from CD34+ seeded polyurethane scaffolds 
over 28 days of culture. The three-dimensional scaffolds used in this work are 0.175 cm3 PU or de-cel-
lularised bone scaffolds, that exhibit a sponge like honeycomb interior for cell culture (Fig. 1A). PU has been 
previously shown to support expansion of cord blood MNCs46. The experimental protocol is outlined in Fig. 1B. 
A population of 0.5 × 106 lineage depleted peripheral blood mononuclear cells (PBMNCs) or CD34+ cells from 
adult peripheral blood were seeded on day 0 and cultured in StemSpan supplemented with dexamethasone, SCF, 
IL-3 and IGF (referred to as basic serum free expansion medium, BSFEM) with the addition of 2 U/mL EPO. We 
hypothesized that the lineage depleted population would contain early CD34− stem cells28 and thus may provide 
a greater diversity of stem cells that could increase the yield of erythroblasts. Cellular egress was measured as the 
cells left behind in the well after moving the scaffold to fresh media; therefore, unlike previous scaffold cultures 
where generally the output resided inside the scaffold, the quantifiable output here was taken to be the cells that 
spontaneously egressed from the scaffold.
Continuous cellular egress from the PU scaffold was observed over a 28 day period (Fig. 1C–F). When PU 
scaffolds were seeded with CD34+ cells, maximum egress occurred on day 10 (4.94 × 105) (Fig. 1C). The line-
age depleted population contains a variable proportion of CD34+ cells (10–15%, data not shown), and signif-
icant reduction in scaffold egress (P < 0.001) occurred when PU scaffolds were seeded with lineage depleted 
cells compared to seeding with CD34+ cells (Fig. 1D). There was continuous egress from PU and human bone 
scaffolds seeded with CD34+ cells although the peak of egress was slightly earlier at day 8 for the bone scaffolds. 
However it should be pointed out that the total cell egress from the bone scaffold was significantly lower than 
the PU scaffold culture (P < 0.01), 2.45 × 106 and 3.90 × 106 for the human bone and PU scaffolds respectively 
(Fig. 1D). Due to difficulties in seeding this more rigid scaffold and the natural variability of pore structure, it is 
possible that fewer cells were seeded and/or retained than in the PU scaffolds. This was supported by the observed 
higher egress from the bone scaffold compared to PU at day 2 of culture, which represents cells that had not been 
retained during seeding alongside egress material, therefore a reduction in expansion capacity would be expected. 
A de-mineralised and de-cellularised bone scaffold was also tested, however this scaffold did not perform well 
for this application (data not shown). Therefore this work confirms that the CD34+ population is the preferential 
seeding material for maximal production and reproducibility, and that PU scaffolds are optimal in terms of cellu-
lar egress compared to the human bone derived scaffolds.
The effect of the inclusion of cytokines on CD34+ cells in PU scaffold cultures. To determine the 
effect of cytokines on the output from CD34+ PU cultures, scaffolds were cultured in BSFEM alone or BSFEM 
containing either EPO or TPO, the latter included for its known influence on HSCs expansion. Figure 1E demon-
strates that the peak of cellular egress in BSFEM was observed on day 14 (3.67 × 105) and slightly earlier at day 
10 for both plus EPO and TPO (4.94 × 105 and 5.92 × 105 respectively). The difference between maintenance in 
a basic media or addition of cytokines was found to be significant for EPO (P < 0.01) and highly significant with 
the inclusion of TPO (P < 0.001) (Fig. 1F).
Alongside 3D scaffold cultures, parallel control cultures of 0.5 × 106 CD34+ cells maintained in 1.5 mL media 
minus a scaffold were set up to compare cell expansion and differentiation in the different culture conditions. 
To mimic the subtractive nature of scaffolds, the average number of cells that egressed from the scaffold culture 
was removed from the control culture. To mimic the transfer of scaffolds to a new well with fresh medium, full 
medium changes were performed for control cultures. Surprisingly, a large number of the control cultures also 
persisted for up to 28 days under all culture conditions tested despite reaching a high-density (Fig. 2A). A limita-
tion of removing the average number of cells however is that material is being removed at random and all cells are 
in the same pool unlike the scaffold which is effectively a subtractive culture; therefore a greater number of CD34+ 
cells may be removed from one culture compared to the next thus causing a reduction in proliferation which leads 
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to the early exhaustion of cultures. This effect is most evident in several BFSEM alone cultures and in cultures 
with EPO where the entire population of cells are exhausted or undergo apoptosis (Supplemental Figure S2). 
The exhaustion of these cultures may therefore be a result of the culture conditions not supporting the terminal 
differentiation of the cells into the erythroid lineage. The average culture progression for each of the three con-
ditions in the control cultures reveals a peak at day 10 for plus EPO (3.18 × 106), day 12 for BSFEM (3.24 × 106) 
and day 14 for plus TPO (3.86 × 106) (Fig. 2A). The peak of control cultures (taken as day 12 for all conditions) is 
the highest production point reached of the control cultures, cells then begin to spontaneously differentiate and 
die. Therefore this peak population point was chosen to compare to the cumulative total cell egress from scaffold 
cultures, which revealed there is only a significant difference (P = < 0.01) with the inclusion of TPO (Fig. 2B).
To investigate whether scaffolds are beneficial to the survival of cultured cells, cell death was assessed in both 
the scaffold and control cultures. Cell death was increased in the controls compared with the scaffold cultures, 
results which were largely unaffected by the presence or absence of cytokines. This increase was found to be 
statistically significant when assessed across the whole culture period, when cultures were maintained in either 
BSFEM or with the addition of TPO (P = < 0.05, Fig. 2C), thus suggesting that the honeycomb structure of the 
PU scaffold may aid in the survival of developing cells.
Surface marker expression in standard 2D erythroid and megakaryocyte cultures. Surface marker 
expression in 2D erythroid and megakaryocyte cultures was characterised using flow cytometry in order to 
Figure 1. Polyurethane and bone donor scaffolds sustain cellular egress for a 28-day period. (A) Scanning 
electron micrographs (SEM) of the human bone donor (left) and polyurethane (PU) (right) scaffolds, scale 
bars are 1 mm and 500 μ m respectively. (B) Schematic of the scaffold culture protocol. Scaffolds are seeded with 
0.5 × 106 lineage depleted or CD34+ cells on day 0 in 100 μ L of BSFEM for 2 hours before being immersed in 
1.5 mL of medium. Scaffolds are transferred to a fresh well of medium every 2 days and the output is formed 
from the previous well. The process continues for the 28 day culture period. (C) Cell counts of egress from PU 
scaffolds seeded with CD34+ cells (blue), bone donor scaffolds seeded with CD34+ cells (red) and PU scaffolds 
seeded with lineage depleted cells (green) cultured in BSFEM with the addition of EPO, across the 28 day culture 
period. (D) Cumulative egress from each scaffold in (C) over the entire 28 day culture period (E) Cell counts of 
egress from PU scaffolds seeded with CD34+ cells in BSFEM (red) or with EPO (blue) or TPO (green) across 
the 28 day culture period. (F) Cumulative egress from each scaffolds in (E) over the entire 28 day culture period. 
Outputs for the CD34+ plus EPO experiments in graphs (C–F) are derived from a single set of experiments. 
N = 3 independent experiments in at least duplicate for PU scaffolds, N = 2 in triplicate for human bone donor 
scaffolds. Error bars represent the standard error of the mean. Significance was tested using students T-test, 
*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
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generate a developmental profile under defined culture conditions. The markers used were: CD34 to identify 
haematopoietic stem and progenitor cells, CD36 which is expressed during the bifurcation point from CMP to 
MEP12,13, CD61 which is expressed on MEPs, megakaryocyte progenitors, megakaryocytes and platelets, GPA 
which is expressed on erythroblasts and reticulocytes and CD14 to identify monocytes and macrophages.
Erythroid and megakaryocyte cultures were observed to display similar cell surface marker profiles during the 
first 5 days of culture, with expression of CD34 reducing, CD61 and GPA low and CD36 increasing (Fig. 3A,B); 
thus providing evidence that cells are initially not restricted to either the erythroid or megakaryocyte lineage. 
From day 6 in culture, GPA expression increases in erythroid cultures. In megakaryocyte cultures CD61 increases 
from day 1, whereas in erythroid cultures CD61 expression remains low throughout. The schematic in Fig. 3D 
provides an overview of erythroid and megakaryocyte markers during standard 2D culture. It is important to note 
that, despite detectable expression of GPA and CD61 in both conditions, the cell surface density (MFI) of GPA in 
megakaryocyte cultures and CD61 in erythroid cultures is very low (Supplemental Figures S1 and S3). By day 11 
mature cell surface markers are expressed including band 3 for erythroid and CD41 for megakaryocyte cultures 
showing the initiation of lineage-specific differentiation (Fig. 3C).
Cells that egress from PU scaffolds exhibit an erythroid progenitor phenotype. The flow cytom-
etry panel described above was applied to scaffold egress throughout the culture period. A high proportion of 
the cells egressed from PU scaffolds seeded with CD34+ cells are early erythroid progenitors as indicated by high 
CD36 and low GPA; although as expected GPA expression was slightly higher upon the addition of EPO (Fig. 4 
and Supplemental Figure S4). Importantly, a small but detectable population of CD34+ cells (5.6%, 7.8% and 
22% in BSFEM plus TPO and plus EPO scaffold cultures respectively at day 16) persists throughout the 28 day 
culture period (Fig. 4). CD34 expression levels reduce as the culture progresses; for example on day 4, MFI is 391 
and decreases to 39 by day 16 when scaffolds are cultured in BSFEM (Supplemental Figure S4). Therefore this 
prolonged egress of early progenitors provides evidence for the retention of input material but also delayed mat-
uration within PU scaffold cultures. CD61 is expressed consistently on 20–30% of the egress population under all 
conditions tested (Fig. 4). The CD34/CD36 expression profile provides further evidence for a persistence of MEPs 
for the duration of the culture with a clear transition of CD34+/CD36− CMP population in the first week of cul-
ture to a CD34+/CD36+ MEP population for the remaining 3 week culture period (Supplemental Figure S5)12,13. 
Expression levels for both GPA and CD61 were consistently low on egressed cells, corresponding to the surface 
Figure 2. Parallel control cultures grown in the absence of scaffolds are sustained for the duration of the 
culture period however cell death is increased in controls compared to scaffold cultures. (A) Cell counts 
of high-density control cultures seeded with 0.5 × 106 CD34+ cells and maintained in 1.5 mL either BSFEM or 
with the addition of EPO or TPO. Dead cells were excluded using propidium iodide. (B) The average cumulative 
egress for scaffolds and the maximal point of control cultures, taken as day 12 for BSFEM, + EPO and + TPO. 
Each culture was seeded with 0.5 × 106 CD34+ cells on day 0. The difference between the cumulative scaffold 
egress and peak of control cultures grown in the absence of scaffolds was found to be statistically significant 
in the plus TPO condition (P = 0.00557) but not in plus EPO (P = 0.05564) or BSFEM (P = 0.06647). (C) Cell 
death was assessed using propidium iodide as per manufacturers instructions and expressed as percentage cell 
death across the BSFEM, + EPO and + TPO conditions in both scaffold egress (red) and control cultures grown 
in the absence of scaffolds (blue), every second day for the 28 day period. Cell death was found to be statistically 
significant between control and scaffold cultures in BSFEM and upon the addition of TPO (P = ≤ 0.05). N = 3 
independent experiments in at least duplicate for PU scaffolds, error bars represent the standard error of the 
mean and significance was tested using the students T-test.
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marker expression observed on early progenitors in the early stages of standard 2D erythroid and megakaryocyte 
cultures (Supplemental Figure S4). Only a small number of CD14 positive cells were detected, however expression 
was variable across cultures, as illustrated by large error bars (Fig. 4).
Surface expression was found to be strikingly similar between the scaffold egress and parallel control cultures 
(that are grown under the same conditions but lack scaffolds) in terms of both levels (MFI) and percentage of 
population (Supplemental Figures S3 and S4). This is consistent with the fact that the scaffold and control cultures 
were seeded with the same CD34+ starting material and indicates that these cultures are generating similar hae-
matopoietic progenitors during the culture’s lifetime. Expression of CD34+ was however, found to be increased in 
control cultures over scaffold egress, suggesting retention within the scaffold structure (Fig. 4 and Supplemental 
Figure S3).
3D cultures enable persistence of CD34+ cells within PU scaffolds. To determine whether an inter-
nal bone marrow “niche-like” environment is established within PU scaffold cultures, cells residing within the 
scaffold at the end point of culture, day 28 were visualised using histology techniques (see materials and meth-
ods). DAPI was used to stain the nucleus but also demonstrates distribution throughout the scaffold (Fig. 5). 
CD44 a marker known to be present on many haematopoietic lineages including the erythroid lineage47 was 
used to identify a large proportion of cells in scaffold sections from all three conditions (Fig. 5). Notably there 
was a persistence of CD34+ cells, consolidating the flow cytometry work above and strengthening the argument 
for retention of CD34+ material and delayed maturation (Fig. 5). In addition, expression of GPA was detected in 
both the plus EPO and TPO cultures, albeit it at a higher level in the plus EPO cultures; however there is very little 
or no expression in the BSFEM cultures (Fig. 5). There is also no evidence of megakaryocytes when using CD42b 
(Fig. 5). Taken together, one explanation may be that the CD34+ cells residing within scaffolds cultured without 
Figure 3. Cell surface expression during standard erythroid and megakaryocyte 2D cultures.  
(A,B) Immunophenotype of cells analysed daily from standard 2D erythroid and megakaryocyte cultures 
expressed as a percentage of the live cell population for each of the following cell surface markers; GPA+ (APC), 
CD61+ (APC Vio770) and CD34+ (VioBlue). Erythroid cultures are first cultured in expansion medium and 
then differentiation medium from day 7, whereas megakaryocyte cultures remain in the same megakaryocyte 
culture medium throughout. (A) Erythroid culture, (B) megakaryocyte culture. (C) Expression of mature 
surface markers band 3 (Bric71) and CD41 (5B12) in both erythroid (blasts) and megakaryocyte (megs) 
cultures on days 3, 8 and 11 of culture; monoclonal primary antibodies were coupled to an APC secondary 
antibody. Expression is shown as a percentage of the total live cell population. N = 3 independent experiments 
with error bars representing the standard error of the mean. (D) Daily analysis of megakaryocyte and erythroid 
cultures as assessed with flow cytometry for 11 days with the following antibodies; CD34, CD36, CD61, CD14 
and GPA. Above erythroid, below megakaryocyte culture. Schematic is a representation of the duration of 
expression in addition to the level of expression for each cell surface marker. N = 3 independent experiments.
www.nature.com/scientificreports/
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added cytokines are retained in a more immature state, with a proportion of cells exhibiting detectable CD34+ 
expression after 28 days of culture in each condition. Finally, detection of mature macrophages was attempted 
using L1 calprotectin marker but no positive cells were detected (Fig. 5), indicating a “niche-like” environment 
exhibiting erythroblastic islands does not develop within the scaffold cultures.
Scaffold egress can be differentiated to the reticulocyte stage. To establish whether cells that 
egress from the scaffold have the potential to differentiate and enucleate to reticulocytes, egress populations from 
days 10 and 18 of culture were frozen and later cultured in standard 2D erythroid culture conditions. Thawed 
cells were first cultured in BSFEM with EPO as an expansion phase for 7 days and then terminally differentiated 
using high EPO, transferrin and insulin for a further 7 days. Importantly egress cells from all scaffold culture 
stages were successfully expanded and differentiated to the orthochromatic erythroblast or reticulocyte stage. 
GPA expression was observed on 90% of cells (Fig. 6A) with the appearance of reticulocytes confirmed using flow 
cytometry by the presence of DNA negative cells coupled with GPA expression (Fig. 6B,C) and cytology analysis 
(Fig. 6D). The remaining nucleated cells have a morphology largely consistent with orthochromatic erythroblasts 
(Fig. 6D).
Cellular progenitors from the egress population expand further post scaffold culture with a fold increase in 
cell number for day 10 egressed cells ranging from 65 fold for + TPO to 100 fold for + EPO; an 83 fold increase 
was noted for egress from BSFEM (Fig. 6E). There was however an increase in cell death and reduction in the 
expansion capacity for cells cultured from day 18, perhaps accounted for by the fact that cellular egress had been 
stored frozen or that the progenitors present may be more mature and so media conditions were not optimal for 
the later culture stages.
Discussion
There is a need for improved approaches to the ex vivo manufacture of erythrocytes. Our aim was to mimic the 
structure of the bone marrow by compartmentalising and therefore restricting the differentiation of CD34+ cells 
in the honeycomb structure of the scaffold. We directly compared the efficacy of de-cellularised human bone 
scaffold with a biocompatible and non-biodegradable PU scaffold for the production of erythroid progenitors. 
Unlike previous studies48,49 that attempted to reproduce the whole of erythropoiesis within the scaffold, we have 
taken an alternative approach to seed CD34+ cells on scaffolds and then monitor the release of differentiating 
Figure 4. Flow cytometry analysis reveals the cells that egress from the scaffolds are largely early erythroid 
progenitors. Cell populations that egress from scaffold cultures were assessed every 4 days using antibodies 
to detect the following populations; CD14 (FITC), CD34 (VioBlue), CD36 (PE), CD61 (APC-Vio770) and 
GPA (APC). Cellular populations are shown as a percentage of the total live cell population for each condition, 
plus EPO, plus TPO and BSFEM. N = 3 independent experiments in at least duplicate, error bars represent the 
standard error of the mean.
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cellular egress from the scaffold. A thorough characterisation of the PU scaffold culture system was performed, 
exploring the cell populations that egress and the retained population within the scaffold. Although imaging and 
flow cytometry has been used before to assess scaffold cultures41,50, to our knowledge it has rarely been used in 
combination and to the extent utilised here.
This study has demonstrated the maintenance of a CD34+ population within PU scaffolds in basic media 
in the presence or absence of key cytokines (EPO, TPO) via immunofluorescence analysis. As the scaffold is 
moved every other day to a new well this provides evidence that is supportive of continued cellular egress being 
generated in scaffold cultures until day 28, testament in itself that early progenitors are retained within the scaf-
fold structure. Erythroid progenitors were released from scaffold cultures for 28 days, although addition of TPO 
provided maximal scaffold egress (Fig. 1E,F). The cells that exit the scaffold can be easily harvested and these cells 
are then replenished every two days. Hence a key benefit of the PU scaffold used here is that it retains a continual 
cumulative pool of cells with further expansion potential. We have also shown that it is possible to seed scaffolds 
with the lineage depleted cell population isolated from peripheral blood (Fig. 1C,D), with potential application 
for culturing patient cells, especially useful if only a single blood sample is available, as the cells could be harvested 
every few days and utilized over the 28 days, however this would need to be explored further in future studies.
By first exploring the surface marker expression in normal 2D erythroid and megakaryocyte culture systems, 
we have shown that CD36, CD61 and GPA can be used to provide a convenient means of identifying approxi-
mately 90% of the scaffold output (Fig. 3). The bulk of the scaffold egress population are CD36+ from day 8 of the 
culture period alongside low CD61 positivity that closely resembled the early stages of the erythroid/megakaryo-
cyte cultures when assessed using the same flow cytometry panel (Figs 3 and 4). This cell surface profile fits with 
the known surface expression profile for the transition between CMP and MEP stage being CD34+/−, CD36+ and 
CD41+ 9,11–13,51. There is also evidence that CD61 is present on MEPs, as we have observed a limited but consist-
ent CD34+/CD61+ population throughout our cultures (data not shown)12. This is consistent with the fact that, 
CD41 and CD61 form the GPIIb/IIIa glycoprotein complex52. In the presence of TPO the CD34+/CD36+ MEP 
population persisted for a prolonged period compared to + EPO and BSFEM conditions, likely explained by the 
known expansion effects of TPO on HSCs23,24.
In addition to the retention of a proportion of cells derived from the original CD34+ population cells and 
then the continued release of progenitors, a significant benefit of scaffolds for the prolonged culture observed 
here compared to control cultures was the lower degree of cell death in PU CD34+ seeded cultures in the culture 
conditions used. Interestingly, there was consistently higher cell death regardless of the presence of exogenous 
EPO or not (Fig. 2C), suggestive that the cellular egress is comprised largely of an EPO independent population. 
EPO dependence occurs at the proerythroblast stage of the erythroid lineage26, consistent with the identification 
of scaffold egress as early progenitors; it is also possible that the cells are releasing small amounts of EPO within 
the scaffolds53 enabling limited support for a population that had transitioned into EPO dependence. Cell sur-
face marker expression profiles using flow cytometry across the BSFEM, EPO and TPO conditions were highly 
homologous giving a largely CD34+/−CD36+GPAloCD61+ population, providing further evidence that mainly 
early erythroid progenitors form the egress population, expression profiles also closely resembled the early stages 
Figure 5. CD34+ cells persist to the culture endpoint within the honeycomb structure of PU scaffolds. 
Polyurethane scaffolds were cultured for 28 days and paraffin wax blocks cut to 10 μ m sections. Scaffold sections 
were probed with CD44 (Bric 235), CD34 (Birma K3), GPA (Bric 256), CD42b (BioLegend), and a macrophage 
marker (calprotectin) and coupled to Alexa 647 secondary antibody (white), DAPI was used to stain the nucleus 
(blue). Images were acquired using a Leica SP5-AOBS confocal laser scanning microscope attached to a Leica 
DM I6000 inverted epifluorescence microscope using the 60x lens (N.A. 1.4), scale bars are 27 μ m, images are 
representative and N = 3.
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(days 1–5) of the standard 2D erythroid and megakaryocyte cultures assessed using the same flow cytometry 
panel (Figs 3 and 4).
Importantly the scaffold egress at the different stages of culture can be expanded further and also differentiated 
to the reticulocyte stage. These data demonstrate that immature progenitors that egress from scaffolds are poised 
to further expand and terminally differentiate into reticulocytes. Reduced expansion and enucleation rates for 
cells at the later time point of day 18 were observed. This could be because the later cells are at different stages 
of proliferation or maturation and therefore exhibit different cytokine requirements resulting in spontaneous 
differentiation or apoptosis. A small number of cells which remained (1–2 × 105) from the day 26 time point after 
analysis were also cultured further in 2D however too few cells were viable for analysis; thus providing evidence 
that expansion and survival becomes noticeably reduced by this point of the culture or that the late progenitors 
that egress at this point are not cryogenically stable (data not shown). Reduced expansion of scaffold egressed cells 
from later stages of the culture may also be indicative that although it is still largely erythroid progenitors that 
form the egress population, the cultures nevertheless are gradually progressing and maturing. Interestingly dif-
ferent rates of enucleation were also observed when scaffolds were cultured in BSFEM alone or with the addition 
of EPO or TPO, again possibly an effect of the cytokines causing cells to be at different stages of differentiation 
and lineage commitment. This would result in reticulocytes being produced at differing time points, possibly 
explaining the variation between the conditions, for example cells in the presence of EPO may be at a later stage 
of differentiation explaining higher enucleation rates.
In summary, we have successfully described, optimised and characterised a simplified porous PU scaffold 
culture system that retains a progressively decreasing population of CD34+ cells or cells derived from the origi-
nal seeded population but also allows continuous egress of erythroid progenitors for harvesting (however these 
do become progressively differentiated over time). This study therefore acts as a foundation for future work, for 
example these scaffolds have the potential added benefit of lineage flexibility due to the continuous production 
of early progenitors that have the potential for directed differentiation down specific lineages, but this will need 
exploring further in future studies. Functionalisation of either this scaffold material or another second-generation 
scaffold to form a biologically enhanced compartmentalised system would provide a means to increase biomim-
icry of the bone marrow microenvironment, thereby introducing the possibility of increasing expansion and 
Figure 6. Early progenitors that egress from scaffold cultures differentiate to reticulocytes. Scaffold egress 
from days 10 and 18 was frozen and then defrosted and cultured in a standard erythroid expansion medium 
for 7 days and then in differentiation medium for a further 7 days to test their capacity to differentiate to 
reticulocytes. (A) GPA percentage positive cells at the endpoint (T168) of culture for each the BSFEM, + EPO 
and + TPO conditions. (B,C) Percentage enucleation at T168 as assessed using GPA and hoescht staining, a 
GPA+ and hoescht negative cell is considered to be a reticulocyte. This is also represented in the dot plot in (C). 
(D) Cells that are not enucleated reticulocytes are largely late orthochromatc erythroblasts as demonstrated by 
cytology analysis. Cells were cytospun and stained with May Grunwald Giemsa stains, images are representative 
and scale bars are 20 μ m. (E) Expansion capacity of the starting material, expressed as fold increase from 
defrosting to the final stage of differentiation. N = 2 independent experiments, error bars represent the standard 
error of the mean.
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therefore the yield. Finally once optimal scaffold composition is achieved there is scope to scale this technology 
up to the bioreactor level and include perfusion in order to increase the capacity of production and potentially 
raise yields of ex vivo generated erythrocytes.
Materials and Methods
Antibodies. CD36, CD61, GPA, CD34 (Miltenyi Biotec), CD14 (BioLegend), Bric 235 (CD44, IBGRL rea-
gents), Birma K3 (CD34, IBGRL reagents), Bric 256 (GPA, IBGRL Reagents), CD42b (BioLegend), Macrophage 
L1 calprotectin (Abcam catalogue number: ab22506).
Peripheral Blood Mononuclear Cell and CD34+ cell Isolation. Peripheral blood mononuclear 
cells (PBMNC) were isolated from platelet apheresis blood waste (NHSBT, Bristol, UK) from healthy donors 
with informed consent. Ethics approval for all experimental protocols was granted by Bristol Research Ethics 
Committee (REC 12/SW/0199), and all methods were carried out in accordance with approved guidelines. 
PBMNC separation was performed using Histopaque 1077 as described previously28,54. CD34+ and lineage 
depleted cells were isolated from PBMNCs using magnetic activated cell separation (MACS, Miltenyi Biotec) as 
previously described28,55,56.
Scaffold Preparation. Polyurethane scaffolds were produced as described previously57. Briefly 3D 
scaffolds were fabricated from dioxin by thermally induced phase separation giving a biocompatible and 
non-biodegradable honeycomb structure. Scaffolds with a pore size of 100–250 μ m and a porosity of 90–95% 
were then manually cut into approximately 0.175 cm3 scaffolds (0.5 cm length by 0.5 cm width by 0.7 cm height) 
by first freezing the foam in liquid nitrogen and cutting to size using a razor blade. Human bone scaffolds were 
obtained with informed consent for research and development use (NHSBT, Liverpool, UK). Ethics approval for 
all experimental protocols was granted by Bristol Research Ethics Committee (REC 12/SW/0199), and all meth-
ods were carried out in accordance with approved guidelines. These consisted of cancellous bone harvested from 
the knee joint of donors and cut using a saggital saw to the approximate size of polyurethane scaffolds. Scaffolds 
were decellularised to a level of 99.92% as previously described58, and gamma irradiated.
Scaffolds, both the PU and the bone, were prepared as previously described46,57. Briefly, scaffolds were trans-
ferred to 70% ethanol and then washed by immersion in phosphate buffered saline (PBS) for 20 minutes. Scaffolds 
were centrifuged at 2,000 rpm for 10 minutes before the removal of PBS and immersion in collagen type 1 solution 
at 1 mg/ml (Sigma) in PBS for 20 minutes with rotation at room temperature. Scaffolds were then centrifuged 
again to allow full dispersal of the collagen through the structure at 2,000 rpm for 20 minutes; washed in PBS and 
centrifuged at 1,5000 rpm for 10 minutes and then exposed to ultra violet (UV) radiation for 15 minutes. The PBS 
was replaced with 70% ethanol for 2 hours at room temperature with rotation. Finally the scaffolds were washed 
twice with PBS to remove residual ethanol and stored in StemSpan (Stem Cell Technologies) with 10% fetal calf 
serum (FCS, Gibco) and penicillin/streptomycin at 100 U/0.1 mg per mL of media respectively (Sigma), for at 
least 2 days to equilibrate at 37 °C with 5% CO2.
Three Dimensional Scaffold Cultures. Scaffolds were dried of storage media using sterilized 3 MM 
Whatmann paper and equilibrated to 37 °C until cell seeding. 0.5 × 106 CD34+ or lineage depleted cells were seeded 
statically in 30–50 μ L of media, as described below, the scaffolds were then incubated at 37 °C with 5% CO2 for 2 hours; 
with media added as required to ensure scaffolds did not dry out. 1.5 mL of basic serum free expansion medium 
(BSFEM) culture media consisting of StemSpan supplemented with; penicillin/streptomycin at 100U/0.1 mg per mL 
of media respectively (Sigma), cholesterol-rich lipids 40 μ g/mL (Sigma), stem cell factor 100 ng/mL (SCF, Miltenyi 
Biotec), Interleukin-3 1 ng/mL (IL-3, R&D Systems), insulin like growth factor-1 40 ng/mL (IGF-1, R&D Systems), 
dexamethasone 1 μ M/mL (Dex, Sigma), with or without thrombopoietin 50 ng/mL (Miltenyi Biotec) and with or 
without erythropoietin 2 U/mL (Bristol Royal Infirmary) was gently added to each scaffold. Full medium changes 
were performed every 2 days by carefully transferring the scaffold between wells of media using tweezers by picking 
up the scaffold gently from a single corner for minimal disruption (see Supplemental Figure S6). Although we were 
very careful during this transfer process a small number of cells that egress may be from the scaffold during this 
transfer process. Scaffold egress was counted using the MACSQuant flow cytometer (Miltenyi Biotec). Cells were 
auto-labelled with propidium iodide (Miltenyi Biotec) at a final concentration of 1 μ g/mL. Dead cells were excluded 
and a live cell count taken as a density per millilitre. For cell death analysis samples were only used where 20% or 
more of the total population was the population of interest.
For two dimensional controls 0.5 × 106 CD34+ cells were seeded in 24 well plates and maintained in equivalent 
culture conditions as described above minus the scaffold. Controls were matched as closely as possible to scaffold 
conditions by removing from the culture the average egress from the corresponding scaffold cultures. For these 
cells and scaffold egress not taken for flow cytometry analysis cells were frozen in 50% fetal calf serum (FCS, 
Gibco), 40% PBS with 10% DMSO (Sigma) and stored in liquid nitrogen until required.
Erythroid expansion post 3D culture. Frozen cells were thawed from liquid nitrogen and cultured as 
described previously for 7 days expansion and then 7 days of terminal differentiation of erythroid progenitors54,59,60.
Erythroid Culture to test for surface marker expression. Isolated CD34+ cells were re-suspended 
in IMDM (Biochrom, Source Biosciences) with 10 μ g/mL insulin (Sigma), 3 U/mL heparin (Sigma), 200 μ g/mL 
Transferrin (Sanquin, The Netherlands), 0.01 g/mL BSA (Sigma) and 6.8 mM sodium bicarbonate (NaHCO3) at 
appropriate density supplemented with; penicillin/streptomycin at 100U/0.1 mg per mL of media respectively 
(Sigma-Aldrich), cholesterol-rich lipids 40 μ g/mL (Sigma-Aldrich), stem cell factor 100 ng/mL (SCF, Miltenyi 
Biotec), Interleukin-3 1 ng/mL (IL-3, R&D Systems), insulin like growth factor-1 40 ng/mL (IGF-1, R&D 
Systems), Dexamethasone 1 μ M/mL (dex, Sigma) and erythropoietin 2 U/mL (Bristol Royal Infirmary). As above 
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without IL-3 for a further 4 days with addition of media where required. For differentiation cells were washed 
three times with PBS and reseeded in IMDM base medium supplemented with 10 U/mL EPO (Bristol Royal 
Infirmary), 10 mg/mL insulin, 3% human AB plasma (Sigma), 1 mM thyroid hormone (T3, Sigma), 40 ng/mL 
IGF-1 (R&D systems) and 0.5 mg/mL holotransferrin (Sanquin, The Netherlands).
Megakaryocyte Culture to test for surface marker expression. CD34+ cells were seeded in 12 well 
plates at a density of 1 × 105/mL in CellGro supplemented with; 100 ng/mL thrombopoietin (TPO, Miltenyi 
Biotec), 10 ng/mL interleukin-1beta (IL1-β , Miltenyi Biotec), penicillin/streptomycin at 100U/0.1 mg per mL of 
media respectively (Sigma). Cells were split and fed when required.
Flow Cytometry Panel. Flow cytometry was performed using 1 × 105 cells labeled with extracellular conju-
gated antibodies for 30 min at 4 °C. Data were collected using a MacsQuant flow cytometer (Miltenyi Biotec) and 
processed using FlowJo Version 10.0.7. The following antibodies were included into a multicolour flow cytometry 
panel; CD34 coupled to VioBlue, CD36 coupled to PE, CD14 coupled to FITC, GPA with APC and CD61 with 
APC-Vio770. Relevant IgG controls were used to remove background signal from each antibody.
Histology and Immunofluorescence. Scaffolds were fixed in 4% paraformaldehyde for 15–20 hours and 
washed four times in PBS for 15 minutes. Scaffolds were paraffin embedded and sectioned using a Leica RM2125 
Microtome into 10 μ m sections floated onto polysine slides (VWR). Slides were first baked at 56 °C for approx-
imately 5 hours and then overnight at 37 °C. Slides were de-waxed by immersion into Histo-Clear (National 
Diagnostics) for 30–45 minutes before rehydration through a series of graded ethanol. For immunofluorescence 
sections were washed once in PBS before blocking with PBS containing 4% BSA (PBSA) for 1 hour. Slides were 
washed 5 times with PBS before incubating with primary antibody (primary and control antibodies are as stated 
in figure legends) for 1 hour, again washed 5 times with PBS and incubated with Alexa 647 secondary antibody 
(Invitrogen) for 1 hour. Slides were washed 5 times in PBS and incubated in DAPI to identify nuclei for 5 minutes 
before a further 2 washes. All steps are carried out at room temperature. For coverslips cells were fixed onto slide 
using 1% paraformaldehyde for 5 minutes before permeabilisation in 0.05% Triton (in PBS) for 5 minutes at room 
temperature. Coverslips were then washed three times and blocked and stained with antibodies as above. Finally 
coverslips and slides were washed and mounted using mowiol (Calbiochem). Samples were imaged using a Leica 
SP5 confocal microscope using a 63x lens (N.A. 1.4) in the Wolfson Bioimaging facility, University of Bristol.
Scanning Electron Microscopy. Scaffolds were cut in half and mounted on a chuck with the centre of the 
scaffold face up. The samples were coated using an Emitech K575X sputter coater with a gold/palladium target 
and viewed with the Quanta 400 FEI Scanning Electron Microscope (SEM) in the Wolfson Bioimaging facility, 
University of Bristol.
Statistical Analysis. Where appropriate statistical analysis in the form of a student’s t test, used to determine 
the level of significance where the following indicates, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. N = 3 for PU scaffold 
experiments with n = 2–3 for internal replicates. N = 2 for bone donor scaffold experiments with n = 3 for inter-
nal replicates.
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